Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
November 14, 2022
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thank you for joining us for Palatin's conference call covering operating results for the first quarter of fiscal year 2023. Please be aware that this call is being recorded. Before we get into our prepared remarks, I want to note that anything Palatin states which is not a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be correct. In addition, actual results could differ materially from what is anticipated because of the various risks and uncertainties described in the company's recent filings with the Securities and Exchange Commission. We ask that you weigh those risks and uncertainties carefully as you evaluate these forward-looking statements concerning Palatin's prospects. At this point, I'd like to introduce your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and glad to have you on the Palatin call for the first quarter of fiscal 2023. Dr. Carl Spana here — I serve as CEO and President of Palatin. Joining me today is Steve Wills, who holds the roles of Executive Vice President, Chief Financial Officer, and Chief Operating Officer at Palatin. Steve, I'll hand things over to you so you can walk through the financials and operating results.
Steve Wills
executiveThanks, Carl. Good morning, good afternoon, and welcome, everyone. I'll begin with some highlights and recent updates. On Vyleesi, which holds FDA approval for hypoactive sexual desire disorder, our aim with the Vyleesi program is to show the value of a commercial product in the marketplace, with the objective of relicensing the U.S. rights to a committed women's healthcare company. For the fiscal first quarter that ended September 30, 2022, gross product sales came to 2.3 million for the quarter ended September 30, 2022, and also for the June 30 quarter, up 64% over the comparable quarter in 2021. Net product revenue rose 13% over the prior quarter, an increase of 445% over the comparable quarter in 2021. Total prescriptions dispensed were up 17% over the prior quarter and rose 108% compared to the comparable quarter in 2021. Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed all increased over the prior quarter and the comparable quarter in 2021. A few other items. On October 31, 2022, Palatin entered into a securities purchase agreement with a certain institutional investor, selling and issuing an aggregate of 1,020,000 shares of our common stock and prefunded warrants to purchase up to 798,182 shares of Palatin common stock.
Steve Wills
executiveAlso, there are common warrants allowing the purchase of as many as 1,818,182 shares of Palatin common stock. Every share of common stock came with one common warrant attached, at a combined offering price of $5.50. That offering closed on November 2, 2022. Gross proceeds reached 10 million, and net proceeds came to roughly 9.1 million. Turning to our reverse stock split, on August 30, 2022, the Board of Directors approved carrying out a 1-for-25 reverse stock split. The split brought the count of Palatin's outstanding common shares down from about 232 million to roughly 9.3 million, while the authorized number of Common Stock shares stayed unchanged at 300 million. Now shifting to the financial results for the fiscal first quarter ended September 30. On revenue, total revenue is made up of gross product sales of Vyleesi, net of allowances, plus accruals. For the quarter ended September 30, 2022, Vyleesi gross product sales to pharmacy distributors were 2.3 million, with net product revenue of a little under $900,000, versus gross product sales of 1.4 million and net products revenue of approximately $160,000 in the comparable quarter of 2021. Gross product sales rose 64%, and net product revenue rose 445%, compared with the same quarter in 2021.
Steve Wills
executiveNow on operating expenses, for the quarter that closed on September 30, 2022, total operating expenses came in at 9.6 million, versus 7.4 million in the same quarter of 2021. That rise in operating expenses came about because research and development costs went up, mainly tied to our ongoing pivotal Phase 3 clinical trial of PL9643 and the Phase 2 clinical trial of oral PL8177, partly offset by lower commercial expenses connected with Vyleesi. Turning to other income and expenses, total other income net is made up mostly of unrealized foreign currency transaction gains of roughly $400,000 for the quarter that ended September 30, 2022, versus approximately 107,000 in the comparable quarter of 2021. On net loss, Palatin's net loss for the quarter ending September 30, 2022 stood at 8.3 million, versus a net loss of 7.1 million in the same period of 2021. The higher net loss for the quarter ended September 30, 2022 compared with the quarter ended September 30, 2021 was primarily attributable to the growth in operating expenses, offset by a rise in net product revenue from Vyleesi. As for cash position, at September 30, 2022, Palatin's cash and cash equivalents totaled 21.2 million, along with approximately 2 million of accounts receivable, versus cash and cash equivalents of 29.9 million and approximately 1.8 million of accounts receivable at June 30, 2022.
Steve Wills
executiveAs of September 30, 2022, cash and cash equivalents stood at 21.1 million, and that figure excludes roughly 9.1 million in net proceeds from the registered direct offering that closed in November of 2022. It also leaves out the 15 million private placement of redeemable convertible preferred stock. That 15 million sits in an escrow account while the investors decide whether to redeem the shares for cash or notes, or to convert them into common stock. At this point, Palatin expects its operating cash runway to last through calendar 2023. With that, I'll hand the call back to Carl. Carl?
Carl Spana
executiveThank you, Steve. Before I get into some of the operating results, I'd like to review the key objectives that I think will help frame those results. Our long-term goals are to establish the melanocortin system as a validated target for safe and effective medicines to treat a variety of inflammatory and autoimmune diseases. and through this process developed a pipeline of innovative drugs with unparalleled safety. Two key parts exist to achieving these objectives. The first is to advance our understanding of how the melanocortin system works by defining the molecular mechanisms and key signaling pathways that support its physiological effects. This research is ongoing in Palatin's laboratory and through multiple collaborations with academic researchers. Our success is measured by our multiple scientific publications and presentations at scientific and medical meetings. The second, more important part is the translation of the science into clinical results and ultimately therapeutics that address unmet medical needs. We are currently enrolling patients in two clinical trials: One is a Phase 3 study in dry eye disease and the second is a Phase 2 study in ulcerative colitis. We are also on track to initiate patient enrollment in a third clinical program, which will be a Phase 2 study in diabetic kidney disease.
Carl Spana
executiveDuring the quarter, Vyleesi kept delivering strong growth across every key metric — sales, revenue, new prescriptions, and refill rates. Through our ongoing efforts, Vyleesi's value to prospective partners continues to rise. Now turning to our clinical programs. Melody 1 — our Phase 3 trial assessing topical PL9643 for dry eye disease — is still enrolling patients, and we anticipate completing enrollment in the first quarter of 2023, with data readout in the second quarter of 2023. As a reminder, back in August, the studies data monitoring committee reviewed data from the first 120 patients who finished the study. That committee advised continuing enrollment to a total of 350 patients. This signals that one or more endpoints looked promising, and we believe the study has been substantially de-risked. Our second clinical program is evaluating an oral formulation of PL8177 — a selective melanocortin receptor 1 agonist — in a Phase 2 study involving ulcerative colitis patients. That study is assessing the safety and efficacy of oral PL8177, using an adaptive design with an interim assessment planned for the first quarter of 2023 and top line data in the second half of 2023. Enrollment is progressing well, and we do not expect any changes to the program timeline.
Carl Spana
executiveUp next, we'll run a Phase 2 clinical trial to assess both safety and efficacy of melanocortin agonist in patients who have diabetic, nephropathy, or kidney disease. The FDA has approved the investigational new drug application for that study, and enrollment of the first patient is expected during this quarter. We anticipate results from this study in the second half of calendar 2023. More details on our clinical programs are available at clinical trials dot gov. During the first quarter of fiscal 2023, our research and clinical programs kept meeting their objectives, and Vyleesi continued posting impressive quarter-over-quarter growth across all key metrics. Steve and I want to thank you for listening to the Palatin first quarter fiscal 2023 conference call. Additional information on our science and clinical programs can be found on our website at www.palatin.com., and additional information about Vyleesi is available at the Vyleesi.com website. Thank you. We'll now open the call to questions. I'm handing it back over to the operator.
Operator
operatorMichael Higgins from Ladenburg Thalmann has the first question. Go ahead, please.
Michael Higgins
analystThanks, everyone. Morning, guys. Congrats on the continued progress. Thanks for taking a couple of questions. Regarding that second front-of-the-eye indication, could you give us an update on your thinking about what it might be?
Carl Spana
executiveWell, Michael, we haven't chosen one as of yet. It could be any of a number of possible indications. And at this point, with three clinical trials currently enrolling patients, we likely won't get that started until we actually reach the second quarter of next year. Our plate is quite full. That said, it might be in glaucoma, or it might be in something tied to corneal transplantation — we have really strong data, preclinical data, that backs clinical catalysts and <<inaudible>> kinds of indication. I believe at this moment, given resources and so forth, we will probably hold steady with the three clinical trials we're enrolling.
Michael Higgins
analystYeah, that’s clear. And just to build on that point — when it comes to a possible back-of-the-eye diabetic macular edema and retinopathy, do you have any newer thinking there, or is the outlook much the same, with those paced after these three are finished?
Carl Spana
executiveOkay, so that's a somewhat different signal, because the timelines in that case are considerably longer. Probably around the first quarter of next year, we'll make a decision regarding a final clinical candidate as well as the route of administration. After that is settled, we'll likely begin the toxicology program, since longer-term tox will be required for that. So that program will most likely keep advancing toward the clinic, though from a clinical perspective it won't enter the clinic until 2024. One thing we're aiming to achieve there — we haven't published it yet, but we'll probably publish it during the first half of next year — is that we have some truly exciting data across various models, based on how our mechanism is performing in that setting. And one of those goals is that we might look to have partnered that a bit sooner than we had previously anticipated. We believe that market is enormous, really dominated only by the anti-VEGFs, and we have a new novel mechanism that has nothing to do directly with affecting new vascularization, which I think will be quite appealing to potential partners. So we'll be looking to do — we will keep moving forward.
Carl Spana
executiveWe might also be considering an earlier clinical — a corporate transaction.
Michael Higgins
analystThat's really useful, thank you. And then moving over to PL8177 and colitis, could you just verify for us whether you're seeing data as things progress? If you are, is there anything you're able to share with us? And then regarding the interim look, what kind of data would you intend to share with us at that point? Thanks.
Carl Spana
executiveThat trial is placebo controlled, then. So we don’t see — I mean, of course we always see safety data, but whatever data comes to us is blinded. So really — that’s the point where we truly get a view from the DMC in Q1 of next year, when we have our initial look at that.
Michael Higgins
analystAnd then at what point do you conduct the post-results work on the primary and secondary indications or endpoints?
Carl Spana
executiveSure. The approach I had in mind is largely the same as what we did with the dry eye data monitoring committee. So they’ll review it, and they’ll be checking — if they — thanks in the trial to continue. That would mean that one — that in all likelihood the primary endpoint is looking good in a favorable way. That means the basic modeling is right, the results coming in are supportive, and it’s likely that you have a positive study as you keep enrolling.
Michael Higgins
analystGot it. All right, I appreciate that. Thank you, everyone.
Steve Wills
executiveOkay, I'll jump in since things have gone a bit quiet. It seems like we're running into some trouble with the Q&A. <<operator_script>> All right. I believe Carl and I — go ahead, operator.
Operator
operatorApologies. <<operator_script>> There are no more questions coming in. So I’ll hand the call back over to Dr. Spana.
Carl Spana
executiveAll right, thank you. I want to express my appreciation to everybody who joined us for Palatin's conference call covering the first quarter of 2023. Michael, thanks for the questions you raised. They assist us in highlighting the genuinely exciting developments taking place at Palatin. Steve, the team, and I are putting in hard work here. I can't fully convey the enthusiasm we feel about how Vyleesi keeps growing. In my view, a lot of people ought to be watching that closely. Considerable skepticism surrounds female sexual dysfunction. What we're accomplishing with Vyleesi, I believe, demonstrates that such skepticism is misplaced, that a rather attractive market exists for it, and that this product will keep expanding. We're truly thrilled that three clinical trials will be underway before the year ends. Plenty of exciting things lie ahead for us in 2023. With that said, thank you, Steve. Thanks to all of you. Have a wonderful day, and we'll speak with you again next quarter. Take care, everyone.
Operator
operatorI appreciate everyone being on today's call. You're welcome to hang up at this point. Operator, please remain connected and wait for additional directions.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.